Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Deals
Biotech
Royalty signs off $2B to bankroll Revolution's RAS cancer drug
Revolution secured the funding infusion from Royalty in return for a slice of the profits if Revolution's lead cancer drug makes it to market.
James Waldron
Jun 24, 2025 9:00am
Sanofi signs €545M deal to explore Formation’s JAK/SYK inhibitor
Jun 23, 2025 9:47am
Otsuka's $670M pact to point Harbour's TCE to autoimmune disease
Jun 23, 2025 6:29am
Taxes, tariffs, interest rates hold key to biotech's future: EY
Jun 18, 2025 9:50am
China's rapid rise creates 'heightened risks' for pharma: PwC
Jun 18, 2025 5:00am
Eli Lilly pays $1B upfront to buy gene editing partner Verve
Jun 17, 2025 4:35am
